Sign in

CIK 0001841387 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Candel Therapeutics, Inc.

Sign in to watch
Ticker
CADL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
522214851
Phone
617-916-5445
Business address
117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
  1. 4 Conversion Director acquired 1,232,910 shares (conversion)
  2. 4 Open-market buy Chief Financial Officer bought 10,125 shares at $8.00 ($81,000)
  3. 4 Conversion Chief Medical Officer acquired 56,096 shares (conversion)
  4. 4 Open-market buy Chief Business Officer bought 6,000 shares at $8.00 ($48,000)
  5. 8-K Event Executive or director change · Bylaws or fiscal year change
  6. 4 Open-market buy Director bought 56,000 shares at an average $7.34 ($410,778)
  7. S-8 Other Securities Offered to Employees in Benefit Plans
  8. 424B4 Offering Prospectus
  9. EFFECT Other Notice of Effectiveness
  10. 3 Insider Initial Statement of Ownership
  11. 3 Insider Initial Statement of Ownership
  12. 3 Insider Initial Statement of Ownership
  13. 3 Insider Initial Statement of Ownership
  14. 3 Insider Initial Statement of Ownership
  15. 3 Insider Initial Statement of Ownership
  16. 3 Insider Initial Statement of Ownership
  17. 3 Insider Initial Statement of Ownership
  18. 3 Insider Initial Statement of Ownership
  19. 3 Insider Initial Statement of Ownership
  20. 3 Insider Initial Statement of Ownership

Page 20 of 22 · 422 filings